Untitled

Baek, Chung Hee; Kim, Hyosang; Yang, Won Seok; Han, Duck Jong; Park, Su-Kil

doi:10.6002/ect.2016.0367

Cited by 8 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bove et al showed that, in patients with renal dysfunction, the safety profile of febuxostat compared to allopurinol was better regarding relative risk (RR) of adverse events [ 80 ]. A study with kidney transplant patients showed that the use of febuxostat in those patients was safe [ 81 ]. Using febuxostat, close monitoring of patients with renal insufficiency is not required.…”

Section: Discussionmentioning

confidence: 99%

Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat

Jordan

Gresser

2018

Pharmaceuticals

View full text Add to dashboard Cite

The paper addresses the safety of febuxostat and summarizes reports on side effects and interactions of febuxostat published by the cut-off date (last day of literature search) of 20 March 2018. Publications on side effects and the interactions of febuxostat were considered. Information concerning the occurrence of side effects and interactions in association with the treatment with febuxostat was collected and summarized in the review. The incidence of severe side effects was much less frequent than mild side effects (1.2–3.8% to 20.1–38.7%). The rate and range of febuxostat side effects are low at doses of up to 120 mg and only increase with a daily dose of over 120 mg. The publications reveal no age-dependent increase in side effects for febuxostat. In patients with impaired renal function, no increase in adverse events is described with a dose of up to 120 mg of febuxostat per day. Patients with impaired liver function had no elevated risk for severe side effects. A known allopurinol intolerance increases the risk of skin reactions during treatment with febuxostat by a factor of 3.6. No correlation between treatment with febuxostat and agranulocytosis has been confirmed. Possible interactions with very few medications (principally azathioprine) are known for febuxostat. Febuxostat is well tolerated and a modern and safe alternative to allopurinol therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat

Jordan

Gresser

2018

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia

Shen

et al. 2018

J Clin Pharm Ther

View full text Add to dashboard Cite

Summary What is known and objective Febuxostat and allopurinol are xanthine oxidase inhibitors for urate‐lowering therapy. The efficacy and safety of febuxostat and allopurinol have been mostly reported in hyperuricemia patients with normal renal function. Here, we aimed to compare the effects of these two drugs in early post‐renal transplant recipients, focusing on evaluating the urate‐lowering effect and recovery of allograft renal function. Methods A retrospective cohort study was performed in early post‐renal transplant recipients with new onset of hyperuricemia receiving febuxostat or allopurinol therapy. Serum uric acid (UA) and estimated glomerular filtration rate (eGFR) were detected on days 3, 7 and 15 and months 1, 3 and 6 after therapy initiation. Liver and blood functions were monitored and other adverse events were recorded. Results and discussion A total of 48 and 33 patients were enrolled in the febuxostat and allopurinol groups, respectively. Significant UA‐lowering effects were observed on day 3 in both groups. Febuxostat caused a more rapid UA decline, starting on day 3 and lasting for 1 month. The most apparent contrast was found in UA level (267.25 ± 93.66 vs 334.18 ± 96.56 μmol/L, P = 0.003) on day 7; 62.5% and 30.3% of patients achieved target UA level in febuxostat and allopurinol groups respectively on day 3 (P = 0.004), but there was no significant difference between two groups from days 15 to months 6. The median times to achieve target UA level were 3 and 5 days in febuxostat and allopurinol groups respectively (P = 0.002). The eGFR levels and recovering rates were gradually upregulated but no significant differences were found between two groups. No abnormities related to febuxostat or allopurinol were observed. What is new and conclusion This is the first comprehensive evaluation of UA‐lowering effects of febuxostat and allopurinol in early post‐renal transplant recipients. Febuxostat caused a marginally quicker serum UA‐lowering effect than allopurinol, but there was no advantage for long‐term use of febuxostat. The drugs had no significant differences in impacting renal allograft function recovery, and both were well tolerated.

show abstract

Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients

et al. 2020

View full text Add to dashboard Cite

This review aim is to critically resume the available clinical evidence supporting the treatment of chronic hyperuricemia with xanthine-oxidase inhibitor activity. For this reason, all of the studies published in English language from 2000 to August 2019 on uric acid-lowering drugs have been carefully reviewed. The terms “serum uric acid”, “xanthine oxidase”, “allopurinol”, “febuxostat”, and “topiroxostat” have been incorporated into an electronic search strategy, alone and in combinations, in both MEDLINE (National Library of Medicine, Bethesda, MD) and the Cochrane Register of Controlled Trials (The Cochrane Collaboration, Oxford, UK). Even if new urate lowering drugs seem of particular efficacy for acute treatment of refractory hyperuricemia, their use is supported by relatively small clinical evidence: On the contrary, large long-term clinical trials have clearly demonstrated that xanthine oxidase inhibitors (namely, allopurinol and febuxostat) are effective, safe and relatively well-tolerated in the most part of patients. They have been largely tested in elderly, in patients affected by crhonic diseases such as heart failure and cancer, and in patients taking a large number of drugs, confirming their safety profile. Recent data also show that they could exert some positive effects on vascular health, renal function and glucose metabolism. Their cost is also low. In conclusion, xanthine oxidase inhibitors remain the first choice uric acid lowering drug for chronic treatment.

show abstract

Untitled

Cited by 8 publications

References 23 publications

Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat

Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat

Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia

Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients

Contact Info

Product

Resources

About